Gene therapy: Advances and limitations

✍ Scribed by Ascher, Nancy L.

• Publisher: Wiley (John Wiley & Sons)
• Year: 1996
• Tongue: English
• Weight: 148 KB
• Volume: 2
• Category: Article
• ISSN: 1074-3022
• DOI: 10.1002/lt.500020513

✦ Synopsis

Recombinant adenovirus vectors are efficient at transferring genes into somatic tissues but are limited for use in clinical gene therapy by immunologic factors that result in the rapid loss of gene expression and inhibit secondary gene transfer. This study demonstrates that systemic coadministration of recombinant adenovirus with soluble CTLA419, which is known to block co-stimulatory signals between T cells and antigen presenting cells, leads to persistent adenovirus gene expression in mice without long-term immunosuppression. This form of immunotherapy greatly enhances the likelihood that recombinant adenovirus vectors will be useful for human gene therapy.

Upregulation of class I major histocompatibility complex antigens by interferon y is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo